PA
SWTX

Profund Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Profund Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,726
Closed -$1.07M – 1090
2025
Q2 		$1.07M Sell
22,726
-508
-2% -$22.6K 0.04% 286
2025
Q1 		$1.03M Sell
23,234
-879
-4% -$40.5K 0.04% 290
2024
Q4 		$871K Sell
24,113
-3,445
-13% -$120K 0.03% 321
2024
Q3 		$883K Sell
27,558
-1,490
-5% -$55.7K 0.03% 356
2024
Q2 		$1.09M Buy
29,048
+362
+1% +$15.2K 0.04% 280
2024
Q1 		$1.41M Buy
28,686
+4,247
+17% +$196K 0.06% 250
2023
Q4 		$892K Sell
24,439
-6,280
-20% -$164K 0.04% 349
2023
Q3 		$710K Sell
30,719
-13,204
-30% -$361K 0.04% 368
2023
Q2 		$1.15M Buy
43,923
+3,453
+9% +$90.7K 0.06% 286
2023
Q1 		$1.04M Buy
+40,470
New +$1.18M 0.06% 289

Other funds holding SWTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Profund Advisors's SWTX Position: Q3 2025 in Review

Profund Advisors sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 22,726 shares — an estimated $1.07M sold.

Profund Advisors first reported a position in SWTX in Q1 2023 and held it in 10 quarters. The position peaked at $1.41M in Q1 2024. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

  • Profund Advisors reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Profund Advisors sold 22,726 SpringWorks Therapeutics shares in Q3 2025, an estimated $1.07M.
  • Profund Advisors first reported a position in SpringWorks Therapeutics in Q1 2023 and held it in 10 quarters.
  • Profund Advisors's SpringWorks Therapeutics position peaked at $1.41M in Q1 2024.
  • 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Profund Advisors's 13F filing for Q3 2025, filed 6 Nov 2025.